Interestingly, our data show that TNBC cells express significantly less MTAP than the more differentiated group composed of Luminal-A breast tumors (Fig 2), which may open the possibility of this new approach to TNBC patients who lack the benefit of endocrine or targeted therapy that is largely used in Luminal and HER2 groups. The gene discussed is MTAP; the disease is breast neoplasm.